What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Virus
- Acquired immunodeficiency syndrome
His primary areas of study are Internal medicine, Gastroenterology, Hepatitis C virus, Immunology and Virology.
His Internal medicine study combines topics in areas such as Lamivudine, Surgery and Viral load.
His Gastroenterology research is multidisciplinary, incorporating perspectives in Coinfection, Pharmacology, Zidovudine and Receiver operating characteristic.
As a part of the same scientific study, he usually deals with the Hepatitis C virus, concentrating on Hepatitis C and frequently concerns with Stavudine.
He has researched Immunology in several fields, including Acquired immunodeficiency syndrome and Transplantation.
His Virology study integrates concerns from other disciplines, such as Mycobacterium bovis, Tuberculosis, Cohort and Microbiology.
His most cited work include:
- Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. (280 citations)
- Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. (208 citations)
- Allograft Rejection Predicts the Occurrence of Late-Onset Cytomegalovirus (CMV) Disease among CMV-Mismatched Solid Organ Transplant Patients Receiving Prophylaxis with Oral Ganciclovir (187 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Gastroenterology, Immunology, Hepatitis C virus and Virology are his primary areas of study.
His work is dedicated to discovering how Internal medicine, Ribavirin are connected with Hepacivirus and other disciplines.
The Gastroenterology study combines topics in areas such as Regimen, Prospective cohort study, Adverse effect and Ritonavir.
His research in Immunology intersects with topics in Acquired immunodeficiency syndrome, Incidence and Transplantation.
His study focuses on the intersection of Hepatitis C virus and fields such as Cohort with connections in the field of Cohort study.
Antonio Rivero works mostly in the field of Virology, limiting it down to topics relating to Hepatitis E virus and, in certain cases, Hepatitis E.
He most often published in these fields:
- Internal medicine (52.22%)
- Gastroenterology (32.59%)
- Immunology (30.70%)
What were the highlights of his more recent work (between 2016-2021)?
- Internal medicine (52.22%)
- Hepatitis C virus (27.53%)
- Gastroenterology (32.59%)
In recent papers he was focusing on the following fields of study:
Antonio Rivero spends much of his time researching Internal medicine, Hepatitis C virus, Gastroenterology, Virology and Hepatitis C.
His study in Internal medicine is interdisciplinary in nature, drawing from both Ribavirin and Viral load.
His study looks at the relationship between Hepatitis C virus and topics such as Coinfection, which overlap with Risk factor and Liver fibrosis.
Atazanavir is closely connected to Lamivudine in his research, which is encompassed under the umbrella topic of Gastroenterology.
His work carried out in the field of Virology brings together such families of science as Hepatitis E virus, Hepatitis E, Genotype, Hepatitis E virus infection and Antibody.
His Genotype research is multidisciplinary, incorporating elements of Virus and Immunology.
Between 2016 and 2021, his most popular works were:
- Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DUAL-GESIDA 8014-RIS-EST45 Trial. (58 citations)
- Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. (56 citations)
- Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study) (45 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Virus
- Acquired immunodeficiency syndrome
His primary scientific interests are in Internal medicine, Hepatitis E virus, Hepatitis E, Gastroenterology and Hepatitis C virus.
His biological study spans a wide range of topics, including Darunavir, Viral load and Emtricitabine.
The concepts of his Hepatitis E study are interwoven with issues in Immunology and Virology.
His Gastroenterology research is multidisciplinary, relying on both Lamivudine and Ritonavir.
As part of his studies on Hepatitis C virus, he frequently links adjacent subjects like Hepatitis C.
His Hepatitis C study incorporates themes from Regimen and Drug.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
